235 related articles for article (PubMed ID: 26823828)
21. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
[TBL] [Abstract][Full Text] [Related]
22. Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma.
Xu YW; Chen H; Guo HP; Yang SH; Luo YH; Liu CT; Huang XY; Tang XM; Hong CQ; Li EM; Xu LY; Peng YH
Gastric Cancer; 2019 May; 22(3):546-557. PubMed ID: 30426295
[TBL] [Abstract][Full Text] [Related]
23. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
Kageyama S; Wada H; Muro K; Niwa Y; Ueda S; Miyata H; Takiguchi S; Sugino SH; Miyahara Y; Ikeda H; Imai N; Sato E; Yamada T; Osako M; Ohnishi M; Harada N; Hishida T; Doki Y; Shiku H
J Transl Med; 2013 Oct; 11():246. PubMed ID: 24093426
[TBL] [Abstract][Full Text] [Related]
24. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
25. Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
Dai L; Tsay JC; Li J; Yie TA; Munger JS; Pass H; Rom WN; Zhang Y; Tan EM; Zhang JY
Lung Cancer; 2016 Sep; 99():172-9. PubMed ID: 27565936
[TBL] [Abstract][Full Text] [Related]
26. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
Akcakanat A; Kanda T; Koyama Y; Watanabe M; Kimura E; Yoshida Y; Komukai S; Nakagawa S; Odani S; Fujii H; Hatakeyama K
Cancer Chemother Pharmacol; 2004 Jul; 54(1):95-100. PubMed ID: 15118836
[TBL] [Abstract][Full Text] [Related]
27. Selective application of neuroendocrine markers in the diagnosis and treatment of small cell lung cancer.
Du J; Li Y; Wang L; Zhou Y; Shen Y; Xu F; Chen Y
Clin Chim Acta; 2020 Oct; 509():295-303. PubMed ID: 32592711
[TBL] [Abstract][Full Text] [Related]
28. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
29. A Highly Efficient Gene Expression Programming (GEP) Model for Auxiliary Diagnosis of Small Cell Lung Cancer.
Yu Z; Lu H; Si H; Liu S; Li X; Gao C; Cui L; Li C; Yang X; Yao X
PLoS One; 2015; 10(5):e0125517. PubMed ID: 25996920
[TBL] [Abstract][Full Text] [Related]
30. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma.
Nakamura S; Nouso K; Noguchi Y; Higashi T; Ono T; Jungbluth A; Chen YT; Old LJ; Nakayama E; Shiratori Y
J Gastroenterol Hepatol; 2006 Aug; 21(8):1281-5. PubMed ID: 16872310
[TBL] [Abstract][Full Text] [Related]
31. Differences in initial NSE levels in malignant and benign diseases of the thoracic wall.
Franjević A; Pavićević R; Bubanović G
Clin Lab; 2012; 58(3-4):245-52. PubMed ID: 22582497
[TBL] [Abstract][Full Text] [Related]
32. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
Yang J; Li R; Li A
Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
[TBL] [Abstract][Full Text] [Related]
33. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival.
Titulaer MJ; Klooster R; Potman M; Sabater L; Graus F; Hegeman IM; Thijssen PE; Wirtz PW; Twijnstra A; Smitt PA; van der Maarel SM; Verschuuren JJ
J Clin Oncol; 2009 Sep; 27(26):4260-7. PubMed ID: 19667272
[TBL] [Abstract][Full Text] [Related]
34. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
Aoki M; Ueda S; Nishikawa H; Kitano S; Hirayama M; Ikeda H; Toyoda H; Tanaka K; Kanai M; Takabayashi A; Imai H; Shiraishi T; Sato E; Wada H; Nakayama E; Takei Y; Katayama N; Shiku H; Kageyama S
Vaccine; 2009 Nov; 27(49):6854-61. PubMed ID: 19761832
[TBL] [Abstract][Full Text] [Related]
35. NY-ESO-1 protein expression and humoral immune responses in prostate cancer.
Fosså A; Berner A; Fosså SD; Hernes E; Gaudernack G; Smeland EB
Prostate; 2004 Jun; 59(4):440-7. PubMed ID: 15065093
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
[TBL] [Abstract][Full Text] [Related]
38. Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.
Valmori D; Souleimanian NE; Hesdorffer CS; Ritter G; Old LJ; Ayyoub M
Clin Immunol; 2005 Oct; 117(1):24-30. PubMed ID: 15994128
[TBL] [Abstract][Full Text] [Related]
39. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.
Kawabata R; Wada H; Isobe M; Saika T; Sato S; Uenaka A; Miyata H; Yasuda T; Doki Y; Noguchi Y; Kumon H; Tsuji K; Iwatsuki K; Shiku H; Ritter G; Murphy R; Hoffman E; Old LJ; Monden M; Nakayama E
Int J Cancer; 2007 May; 120(10):2178-84. PubMed ID: 17278093
[TBL] [Abstract][Full Text] [Related]
40. Six autoantibodies as potential serum biomarkers of hepatocellular carcinoma: A prospective multicenter study.
Okada R; Otsuka Y; Wakabayashi T; Shinoda M; Aoki T; Murakami M; Arizumi S; Yamamoto M; Aramaki O; Takayama T; Wakiyama S; Yanaga K; Amikura K; Kaneko H; Shimada H
Int J Cancer; 2020 Nov; 147(9):2578-2586. PubMed ID: 32574375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
